Gordon Troup elected Neoprobe chairman
This article was originally published in Scrip
Neoprobe Corporation has named Gordon Troup chairman of the board, succeeding Carl Aschinger who served as chairman since 2007. Mr Troup has been a member of Neoprobe's board since 2008, and vice-chairman since July 2010. Before his retirement in 2007, he served as president of the Nuclear Pharmacy Services business at Cardinal Health.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.